Mistrust in the Oxford jab is soaring across the EU after several member states suspended the vaccine over fears it caused blood clots. And after the resumption of its use, despite reassurances from both the European Medicines Agency (EMA) and the World Health Organisation (WHO), some member states have limited its use to people under the age of 55 to 60.
The controversial move, reported by Express.co.uk, has triggered an angry backlash in the UK where the vaccine was developed.
One reader said: “Emmanuel Macron certainly did not listen to EMA when he opened his mouth and this is what happens when scaremongering is done. People then do not want to have it!”
Another said: “The EU made their bed, now they can lay in it.
“This will come back to bite them in the rear, without a doubt.”
Another said: “The EU can’t use the vaccines because they made people lose confidence in it. But they won’t export it either.
“They will go down in history as having caused deaths in their own countries, the UK and the rest of the world.”
Another reader said: “Out of jealousy the EU trashed the AtraZeneca vaccine and now reaps what it sowed.”
Another said: “Why are they preventing the shipping of this vaccine to the UK if they are not using and can’t get their lot to use it?”
And another said: “They wanted it. They trashed it. They stock-piled it. They stop others from having it. Now they can’t give it away.”
READ MORE: Macron sidekick Beaune attacks AstraZeneca: ‘They made fun of us’
In Spain, confidence in Vaxzevria, the official name for the vaccine, has nosedived after the Government changed its guidance on who can receive the vaccine.
Earlier this week health officials approved its use for those between 60 and 69.
Since then, Madrid residents have been reluctant to come forward, with only around 45 percent of those asked, confirming their appointments.
Prime Minister Pedro Sanchez said: “From a political point of view our decisions will always be absolutely based on scientific and technical criteria to guarantee firstly the lives of our people and our country’s public health and also to ensure the vaccination process is a success.”
In the UK, regulators have recommended that people aged 18 to 29 should be offered alternatives to the AstraZeneca vaccine, saying there was a possible link between the jab and “extremely rare” blood clots.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the benefits still outweigh the risks overall, but while it has not concluded that the AstraZeneca vaccine causes rare brain clots, it said the link is getting firmer.
The MHRA said figures suggest the risk of rare blood clot is the equivalent to four people out of every million who receive the AstraZeneca vaccine.